INNV-21. IN NEWLY-DIAGNOSED GLIOBLASTOMA, FRAILTY/SARCOPENIA PREDICTS 30D MORBIDITY & 30D, 90D, AND OVERALL MORTALITY AS ACCURATELY AS CURRENT STANDARDS

INTRODUCTION: Identification of novel prognostic biomarkers for glioblastoma (GBM) could stratify patients between aggressive or palliative treatments. Frailty, as measured by sarcopenia (lack of muscle mass), has been proven to predict survival in cancers. We evaluate whether the frailty/sarcopenia...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Neuro Oncol
Главные авторы: Zakaria, Hesham, Chandra, Ankush, Macki, Mohamed, Robin, Adam, Walbert, Tobias, Chang, Victor, Kalkanis, Steven, Lee, Ian
Формат: Artigo
Язык:Inglês
Опубликовано: Oxford University Press 2019
Предметы:
Innovations in Patient Care
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC6847745/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz175.564
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы